According to the Shanghai Pharmaceutical announcement, Shanghai Pharmaceutical Ruier, a subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” for triprostenil diethanolamine inhalation powder approved and issued by the State Drug Administration and agreed to carry out clinical trials with this product. The drug is a Class 2.2 improved innovative drug. It is intended to be used to treat pulmonary hypertension to reduce symptoms caused by exercise. As of the date of disclosure of the announcement, a total R&D cost of about 21.41 million yuan has been invested. Currently, it has not obtained marketing approval in any country or region in the world. This approval has no significant impact on the company's business situation. There is uncertainty about the development of new drugs. Investors are kindly requested to be aware of the risks.

According to the Shanghai Pharmaceutical announcement, Shanghai Pharmaceutical Ruier, a subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” for triprostenil diethanolamine inhalation powder approved and issued by the State Drug Administration and agreed to carry out clinical trials with this product. The drug is a Class 2.2 improved innovative drug. It is intended to be used to treat pulmonary hypertension to reduce symptoms caused by exercise. As of the date of disclosure of the announcement, a total R&D cost of about 21.41 million yuan has been invested. Currently, it has not obtained marketing approval in any country or region in the world. This approval has no significant impact on the company's business situation. There is uncertainty about the development of new drugs. Investors are kindly requested to be aware of the risks.